Gilead Sciences, Inc.
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
2256 articles about Gilead Sciences, Inc.
-
Gilead Submits New Drug Application To Japan’s Pharmaceutical And Medical Devices Agency For Tenofovir Alafenamide (TAF) For Patients With Chronic Hepatitis B Infection
3/31/2016
-
Gilead Lost Top Cancer Scientist Right Before Zydelig Troubles Hit
3/30/2016
-
3 Biotechs that Don't Require Day-to-Day Monitoring
3/30/2016
-
ContraVir's CMX157 Bests Gilead's Tenofovir AF (TAF) Against Hep B Virus in Head-to-Head In-Vitro Study
3/29/2016
-
Despite a Streak of Bad Luck, Gilead Clinches Deal for Foster City HQ Expansion
3/28/2016
-
Gilead Ordered to Pay Merck & Co. $200 Million in Damages Over Hep C Patent Dispute
3/25/2016
-
The 8 Best Pharmaceutical Companies to Work for
3/24/2016
Looking for the best pharmaceutical companies to work for? Here's the list of the top 8 pharma companies that are hiring right now. So, let's check the list.
-
More Bad Luck for Gilead as Merck & Co. Wins Victory in Hep C Patent Dispute
3/24/2016
-
After Oncology Trial Failures, Investors Urge Gilead to Buy, Buy, Buy
3/23/2016
-
Gilead Stock May be Cheap Right Now But Investors are Skittish and Doubtful
3/18/2016
-
Gilead Shuts Down Six Zydelig Trials Following European Medicines Agency Review
3/17/2016
-
Gilead's Zydelig Under Review in Europe Following Reported Deaths, Side Effects When Combined With Other Drugs
3/15/2016
-
Gilead To Present At The Barclays Global Healthcare Conference On Tuesday, March 15
3/11/2016
-
Gilead, Merck & Co. Duke It Out Over Hep C $1,000-Pill Royalties
3/8/2016
-
Gilead To Present At The Cowen and Company 36th Annual Health Care Conference On Monday, March 7
3/7/2016
-
Gilead Announces Settlement Method For 1.625% Convertible Senior Notes Due 2016
3/7/2016
-
FDA Green Lights Gilead’s Odefsey to Treat HIV-1 Infection in Certain Patients
3/2/2016
-
Health Canada Issues Notice Of Compliance For Gilead's Truvada For Reducing The Risk Of Sexually Acquired HIV Infection
2/29/2016
-
Gilead Exec's Job Description: To Sell a $1,000 Pill for $10 Without Losing Money
2/29/2016
-
European CHMP Adopts Positive Opinion For Gilead’s Fixed-Dose Combination Descovy (Emtricitabine/Tenofovir Alafenamide) For The Treatment Of HIV
2/26/2016